The stock has been in a pronounced downtrend over the observed period, with the price declining from over $22 in October 2025 to around $12 by late March 2026. Short-term performance has been extremely weak, with the stock down 40.17% over the last three months and 11.70% over the past month, significantly underperforming the broader market as indicated by relative strength figures of -32.85 and -3.83, respectively. The current price of $12.45 is near the 52-week low of $11.90, trading at just 49.9% of the 52-week high of $24.95, indicating the stock is in a deeply oversold position on a price basis.

Revenue for the latest quarter (Q3 2026) was $281.9 million, showing a solid year-over-year growth of 19.84%. However, profitability remains a significant challenge, with the company reporting a net loss of $36.0 million and a negative net margin of -12.8%, though this is an improvement from the deeper losses in prior quarters. The company's financial health shows a current ratio of 0.89, indicating potential short-term liquidity pressure, but it maintains a negative debt-to-equity ratio of -0.19, signifying a net cash position. Operational efficiency is mixed, with a positive Return on Equity (ROE) of 5.65% but a negative Return on Assets (ROA) of -2.55%, reflecting the impact of losses on its asset base.